lonafarnib (Sarasar)
Jump to navigation
Jump to search
Indications
Mechanism of action
- farnesyltransferase inhibitor
- putatively inhibits prenylation of progerin
- may delay mortality in patients with progeria
More general terms
Additional terms
References
- ↑ Gordon LB, Shappell H, Massaro J et al Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA. 2018;319(16):1687-1695 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29710166 https://jamanetwork.com/journals/jama/fullarticle/2679278?
Hisama FM, Oshima J. Precision Medicine and Progress in the Treatment of Hutchinson-Gilford Progeria Syndrome. JAMA. 2018;319(16):1663-1664. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29710145 https://jamanetwork.com/journals/jama/fullarticle/2679255 - ↑ Gordon LB, Kleinman ME, Massaro J et al Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation. 2016 Jul 12;134(2):114-25. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27400896 Free PMC Article